StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
KLIN.SW$11.15+1.42%
Fair $11.15+0.0%

KLIN.SW

Klingelnberg AG

Industrials / Specialty Industrial MachinerySwiss

$11.15

+0.15 (+1.42%)

Fairly Valued+0.0%Fair Value $11.15Fund rank 25/100 · Data gapFallback financials|
SA 32/D
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $9.9M · quality 37.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 23/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · KLIN.SWLocal privado en este navegador · Klingelnberg AG
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$99M

P/E

9.9x

↓

EV/EBITDA

3.7x

↓

ROE

7.0%

↑

Gross Margin

58.6%

↑

Debt/Equity

N/A

•
52-Week Range$11
$10$14

TradingView lightweight chart

KLIN.SW price, volumen y niveles de valoración

Último $10.70Periodo -79.6%
Fair value: $11.15

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+24.9%

FCF CAGR

—

FCF margin

3.2%

FCF / Net income

1.00x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $309.1M · net income $10.0M · FCF $9.9M

2022-FY → 2025-FY

Gross margin

58.6%+2.4% pts

Operating margin

5.0%+15.2% pts

Net margin

3.2%+16.9% pts

FCF margin

3.2%+44.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$309.1M$309.1M$303.5M$309.0M$158.6M
Net Income$10.0M$10.0M$17.2M$20.8M$-21.7M
EBITDA$22.5M$22.5M$29.5M$27.0M$-14.5M
EPS1.131.131.952.35-2.45
Gross Margin58.6%58.6%57.7%53.2%56.2%
Operating Margin5.0%5.0%5.0%7.5%-10.3%
Net Margin3.2%3.2%5.7%6.7%-13.7%
Balance Sheet
Current Ratio1.501.50———
Cash Flow
Free Cash Flow$9.9M$9.9M$15.2M$-2.6M$-66.1M
Returns
ROE7.0%7.0%12.2%16.4%-20.7%
Valuation
P/E9.879.878.567.77—
EV/EBITDA3.673.674.445.65—
P/B0.690.691.051.271.27
Growth & Yield
Revenue Growth1.8%1.8%-1.8%94.8%—
EPS Growth-42.1%-42.1%-17.0%195.9%—
Dividend Yield4.7%4.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-4.3%

fácil

EPS terminal req.

$0.99

Spread vs growth

-37.7%

5Y implied EPS CAGR

1.2%

fácil

EPS terminal req.

$1.20

Spread vs growth

-43.2%

10Y implied EPS CAGR

5.5%

razonable

EPS terminal req.

$1.93

Spread vs growth

-47.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -12.4%

Total return

-12.4%

Start / end P/E

6.6x → 9.5x

EPS bridge

1.95 → 1.13

Residual

-18.1%

EPS growth-42.1%
Multiple rerating+43.1%
Dividend+4.7%
Residual / FX / buybacks / cross-term-18.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.